OrSense presents non-invasive Hb monitor on World Blood Donors Day

On the World Blood Donors Day, OrSense Ltd., developer of monitors for non-invasive measurements of key blood parameters, presents its non-invasive hemoglobin (Hb) monitor, which holds potential to enhance recruitment and retention of blood donors.

Dr. Emma Castro, CEO of the Transfusion Center of the Spanish Red Cross in Madrid said, "A non-invasive system for the measurement of pre-donation Hb is eagerly awaited by both donors and staff. Our donors are very excited about the implementation of the new OrSense system and we are looking at it as a tool that will contribute to enlarge our blood donor community. Pricking the finger is experienced by our blood donors as the worst part of the process, thus the new apparatus will change their experience from a deterring to a pleasant one. Non-invasive Hb monitoring usher a new era for blood donation centers."

Lior Ma'ayan, CEO of OrSense, said, "Our non-invasive Hb monitor, the first and only non-invasive Hb monitor available for use, increases donors and staff safety and allows for simple operation by the staff. All sides have to gain from non-invasive pre-donation Hb measurements: it dramatically increases donors' comfort, and thus, we believe, will boost recruitment and retention of blood donors and encourage young, first time donors to donate blood."

Dr. Castro will deliver an oral presentation discussing OrSense's non-invasive monitor in the upcoming National Congress of SETS, the Spanish transfusion society, to be held in Malaga, Spain on June 15-17. In her talk, entitled "Evaluation of a new non-invasive system for the determination of Hb pre-donation," Dr. Castro and her team show that OrSense's non-invasive device achieves comparable results to those of invasive, commonly used techniques.

A similar conclusion was reached by Dr. R.N. Makroo from the Indraprastha Apollo Hospital in Delhi, India, who will be presenting his results at the Regional Conference of ISBT, the international society of blood transfusion, to be held June 18-22 in Lisbon, Portugal. Another study on the use of non-invasive Hb for anemia screening will be presented at ISBT by Aharon Weinstein from OrSense and Prof. A. Kornberg from the Department of Hematology and Blood Bank, Assaf Harofeh Medical Center, Israel.

OrSense non invasive Hb monitor performance was highlighted in a fourth study, during Euroanesthesia 2011 conference of the Europeans Society of anesthesia, held this week in Amsterdam, The Netherlands. The study, directed by Prof. P. Singer from the General ICU Rabin Medical Center, Israel and Aharon Weinstein from OrSense, shows that OrSense's device is able to accurately track rapid changes in Hb levels, and maintains reliability even at very low Hb blood content. The publication focuses on hemorrhage that was emulated by hemodilution. OrSense's non-invasive readings were compared to invasive, arterial blood samples. Reference Hb values ranged from 8.4 g/dl to 15 g/dl. The mean bias between NBM readings and the arterial reference values was 0.3 g/dl. The correlation was 0.9 and the standard deviation (SD) of error was 0.7 g/dl. The average personal SD was 0.5 g/dl.

Source:

 OrSense

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study links menopause hormone therapy to varied heart and blood clot risks